Ocuphire Pharma (NASDAQ:OCUP) Upgraded by Zacks Investment Research to Hold

Ocuphire Pharma stock has undergone multiple analysts rating changes in the recent past.  Ocuphire Pharma Upgraded by Zacks Investment Research on 10/14/2021. In a note to investors, the firm issued a new rating of Hold. The analysts previously had rating of Sell.

Shares of Ocuphire Pharma traded down -$0.09 on Wednesday, reaching $4.38. 71 shares of the stock traded hands, compared to its average volume of 248415. Shares of Ocuphire Pharma were trading at $4.38 on Wednesday. The firm’s 50 day moving average is $4.72 and its 200 day moving average is $6.17.Ocuphire Pharma has a 12 month low of $4.05 and a 12 month high of $13.81. While on yearly highs and lows, Ocuphire Pharma’s today has traded high as $4.49 and has touched $4.05 on the downward trend. See More Analyst Rating at: RATING

Ocuphire Pharma Earnings and What to expect: 

Ocuphire Pharma last released its quarterly earnings data on August 12th, 2021. The reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by $0.14. The firm earned $0.10 million during the quarter. Ocuphire Pharma has generated ($5.28) earnings per share over the last year. Earnings for Ocuphire Pharma are expected to grow in the coming year, from ($4.16) to ($1.59) per share. Ocuphire Pharma has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

Earnings for Ocuphire Pharma are expected to grow in the coming year, from ($4.16) to ($1.59) per share. The P/E ratio of Ocuphire Pharma is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Ocuphire Pharma is -0.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Ocuphire Pharma (NASDAQ:OCUP) Moving Average Technical Analysis

5 day Moving Average is $4.38 And 5 day price change is -$0.08 (-1.79%)  with average volume for 5 day average is 140,080. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $4.93 and 20 day price change is -$0.53 (-10.79%) and average 20 day moving volume is 233,230. 50 day moving average is $4.72  and 50 day price change is -$0.29 ( -6.21%)  and with average volume for 50 days is : 348,774. 200 day moving average is $6.17  and 200 day price change is -$1.53 (-25.89%)  and with average volume for 200 days is : 694,614.

Other owners latest trading in Ocuphire Pharma :

  • On 8/25/2021 shares held by Marshall Wace LLP were 329,131 which equates to market value of $1.74M and appx 0.00% owners of Ocuphire Pharma
  • On 8/23/2021 shares held by Morgan Stanley were 13,660 which equates to market value of $72K and appx 0.00% owners of Ocuphire Pharma
  • On 8/17/2021 shares held by Man Group plc were 14,900 which equates to market value of $79K and appx 0.00% owners of Ocuphire Pharma
  • In total Institutional ownership equates to Institutional Ownership Percentage: 6.33% for Ocuphire Pharma

See More Analyst Rating at: RATING